text:
We see periodic complaints about it's accuracy and functionality.
My numbers don't add up!and
I can't get it to ignore my visits to my blog!and
When I check my stats in the late afternoon, I show a number of page views for "today". If I check my stats in the evening (just a few minutes later, maybe), the stats for "today" show zero and the numbers, just seen for "today", now show for "yesterday".
There are multiple discussions in Blogger Help Forum: Something Is Broken, which open with one of the above topics, and which contain "answers" describing another of these concerns.
Some of these problems are caused by Blogger coding or design deficiencies, others by misconceptions of the blog owners, and still others are cause by security settings on the computers of the blog owners and blog viewers.
Until we understand the etiological nature of these problems, they will never be solved.
My Numbers Don't Add Up!
Some bloggers are treating their Stats displays like a balance sheet. They look at numbers by browser, by country, and by post, total up the figures in each category, and observe that they get different totals for each.
Unfortunately, stats can't display more than 10 countries or posts in any time period, shifting trends over different time periods, or pageviews generated for archive retrievals, label searches, and main page activity, as well as individual posts.
The bottom line here is that you should not expect any totals to add up to any definitive figure, such that totals between each category would be expected to balance, like your checkbook.
My Numbers Don't Start When I Started The Blog!
Some blog owners start a blog in 2013 - then wonder why Stats seems to show visitor activity in 2012.
This can happen because of several scenarios.
- Somebody could have published a blog, using your URL, before you started using that URL. You could intentionally taken over an active URL - or you could have accidentally gotten that URL, after the previous owner abandoned it.
- You could be looking at referer spam counts.
- You could be seeing random traffic, from people who mistyped the URL of another Blogger blog.
Whatever the cause, those numbers are yours. Stats has no options to "correct" or "reset" your pageview counts.
The Option To "Ignore My Own Pageviews" Doesn't Work, Immediately
The ability to have Stats ignore activity by the owner requires a cookie which carries this setting, from when you the blog owner select the option, to when you the blog owner surf the blog. The cookie is unique to one browser, on one computer - and in some cases, to different people on one computer.
If you have more than one browser, more than one computer, or more than one person using a shared computer, you will need to consistently select "Don't track ..." for each browser, each computer, and each user.
The cookie must be accessible across domains, since it's created from "Blogger.com", and read from "BlogSpot.com" - or whatever domain your blog is published under. It must also be persistent across browser restarts. The cookie will also be a problem, if you have more than one Blogger / Google account.
When you, the blog owner, use a computer which blocks third party scripts, or which deletes cookies when the browser is restarted, your pageviews will be counted by Stats, when you surf your blog. If you login to a second Blogger account, your pageviews will be counted by Stats.
If you share a computer with someone else - either with shared login sessions, or unique system logins - make sure that you are in agreement with the other person, or that you consistently use your own login session. A shared computer, logged in under another person's login, will not have access to cookies that you create, under your login. And if the other person clears cookies, under a shared login, your cookies will be gone.
And note that most anti-virus and firewall suites - and some high end NAT routers - also contain cookie and script filters. Every one of these accessories, that you have on your computer or your network, should be carefully checked.
Block tracking cookiesis a setting that one blogger found enabled, when he examined his firewall suite.
(Update 2015/03): If your problem is caused solely by a blocked third party "Don't track ..." cookie, you may have a workaround, for this problem.
Yesterday Starts During My Evening - Not At My Midnight
From observing the complaints about stats resetting its counters daily, it appears that it's setup to reset counts for all blogs, simultaneously, at midnight UTC (aka "GMT"). Some blog owners contend that it would be more useful to them if the counters for their blogs was to reset according to their local midnight.
Imagining this to be a separate option for each blog, requiring over 24 separate reset processes (a minimum of one schedule per major time zone, worldwide), it's impossible to imagine how pageview counts could be reset at midnight, for all Blogger blogs. I suspect that using the UTC clock, to schedule all blog resets, is the only real possibility here.
The bottom line here? Just as with some Blogger problems in general, some problems with Stats may start with our computers.


text:
Degree or Program Details
Earth, Environmental and Geographical Sciences Cluster Minor
For earth, environmental and geographical sciences department non-teaching majors only.
For department information or additional degree requirements, click here
Total Credits Required for Minor | 20 |
Note: The cluster minor may consist of courses that emphasize the physical, cultural or applied areas of the primary themes of the department. Approval of a cluster minor must be obtained from each department contributing two or more courses to the minor. Courses comprising the cluster minor must be submitted to the Registrar's Office during the student's third semester at NMU.

subset: commoncrawl


text: Dennis Rodman's Father Had 29 Children By 16 Women And Is Actually Named PhilanderBarry Petchesky7/19/12 2:30pmFiled to: Dennis RodmanNbaPhilander rodmanAppicNewsPhilippines50EditPromoteShare to KinjaToggle Conversation toolsGo to permalinkDennis Rodman's father, an air force pilot, abandoned his family when Dennis was just three years old. He moved to the Philippines and opened a bar. (He now runs Rodman's Rainbow Obamaburger restaurant.) After playing an exhibition game in Manila yesterday, Dennis finally met Philander Rodman Jr., sort of: they "only had time for greetings and handshakes." [AP]AdvertisementSee also: Philander Versus The VolcanoReply50 repliesLeave a reply


text:
404 File Not Found
Host by NetBox Version 2.8 Build 4128
Mudpie Initial Baby Boy Blue Initial Ceramic Polka Dot Piggy Bank, Letter G
This little piggy wore blue polka dots! White ceramic piggy bank sports blue polka dots and blue-on-blue polka dot decorated ears and dimensional letter. Piggy is 6" x 7.5" and arrives in a pin striped gift box. Blue Initial Ceramic Polka Dot Piggy Bank is a gift that can be used and appreciated for years. Start baby's signature style from the get-go with selections from Mud Pie Baby's Initial Collection.
Features include:
•Adorable ceramic Piggy Bank is a gift that can be used and enjoyed from the time he's in a crib to his big-boy bed and beyond
•White ceramic piggy with big blue dots plus blue-on-blue polka dot ears and a dimensional letter G
•Piggy is 6" x 7.5" and arrives in a pin striped gift box
•Start his signature style from the get-go with Mud Pie's Initial Baby Boy Collection and a personalized gift featuring baby's first or last name initial
•For more than 25 years Mud Pie Baby has been combining quality and attention to detail with adorable design flair to create big ideas for little ones
List: $23.69
Initial Baby Boy Blue Initial Ceramic Polka Dot Pi |
Currently Unavailable |
For the purchase limit reached item, please choose a quantity to Add to Registry
Quantity:SELECT A CART
Please choose which cart you want to add the item.
By choosing one of the above, you are able to shop for both yourself and a registrant at the same time. Once you are ready to checkout your items will be waiting for you in both your personal and registry shopping carts.
Still need assistance?
Please contact us at 1-800-Diapers (1-800-342-7377)


text:
Source: George S. Mack of The Life Sciences Report (9/4/12)
Managing Director Greg Wade of Wedbush Securities doesn't use a cookie-cutter approach to picking biotechnology stocks. He directs investors to companies with strong science, well-executed clinical studies and data that points toward future success. In this exclusive interview with The Life Sciences Report, Wade shares his favorite names and the compelling stories behind each company.
The Life Sciences Report: The Wedbush Management Conference was held in New York City in mid-August. What was the mood of institutional life sciences investors?
Greg Wade: The investors I talked to were upbeat. Most were looking for new ideas. They were optimistic that the marketplace would be stable enough in the latter half of 2012 for folks to make money in equities with good fundamentals. It was a very positive outlook.
TLSR: You also had some private companies presenting at the conference. What kind of exit strategies are they looking for? Do most of them want to do an initial public offering (IPO)?
GW: Yes. The valuations that can be achieved with public offerings are sufficiently positive that some private companies are considering them as viable financing options. The investing community, too, is more broadly considering IPO candidates, which is heartening for companies looking to meet with investors.
TLSR: Are companies expected to have clinical assets before they think about going public?
GW: That almost always depends on the indication and whether the data at hand predicts ultimate clinical success. Certainly, more advanced companies are going to have a broader audience of potential investors, but we've also seen promising, unique technology platforms. Companies with these platforms could attract the type of capital that would propel them to the clinical stage.
TLSR: We have had a wonderful rally in biotech since the end of last year. In talking with investors, especially institutional investors, do they feel the rally is going to continue?
GW: One reason for the strong rally that must be recognized is a real decline in volatility. That decline has created a very healthy financing environment for development-stage companies, and is very supportive of a strong overall index. Most of the investors I talk to are not trading the market; they are looking for specific investment ideas that might be well financed and have immediate attractive valuation.
TLSR: Could we talk about some companies that you like?
GW: There are two companies on the Wedbush Securities Best Ideas List, currently in my coverage, that I'd like to discuss. The first is Pharmacyclics Inc. (PCYC:NASDAQ), which we added when the stock was priced in the low-teens. It has since blown through our price target—up well over 350% since it was added and continuing to move up. The stock is trading at about $63 per share presently.
Investors clearly appreciate the safety and efficacy of the company's lead drug ibrutinib (PCI-32765), and the global development partnership that the company has struck with Janssen Biotech Inc., a subsidiary of Johnson & Johnson (JNJ:NYSE). The expected results from phase 3 studies and the absence of a requirement to finance the company's participation in global development of the drug make this a must-own hematology/oncology company. We continue to recommend the stock to investors, believing that there's some further work required on our model to properly value the biggest opportunity for the drug, which we think is as a chronic treatment for chronic lymphocytic leukemia (CLL).
TLSR: Ibrutinib is a small-molecule Bruton's tyrosine kinase (BTK) inhibitor, and it is well into phase 3. The company must have seen some outstanding phase 2b data for the stock to be up nearly 500% over the past 12 months.
GW: Yes. Even the phase 1 data—the first experience in humans—were incredibly striking, with a response rate of about 80% in patients. In the CLL setting, close to 90% of patients remaining on treatment were without progression, suggesting that the BTK target, at least in the CLL setting, might be an Achilles' heel for the disorder in some patients. Chronic therapies for hematologic malignancies have attracted significant interest from investors, the CLL market being the most well recognized. With CLL, you have a patient population of 115,000 in the U.S. alone, and the company has a dramatic opportunity to market a high-priced, safe medicine that folks will take every day for treatment of their leukemia. That is the biggest driver, and timing is really a question of when we'll have the first phase 3 data and how quickly the U.S. Food and Drug Administration (FDA) will act on the application.
TLSR: Looking at the performance of ibrutinib, are we apt to see an earlier approval than might be anticipated?
GW: I think the Street is comfortable with the idea that the CLL phase 3 study, which is beginning now, will probably finish early so the company can provide data for a new drug application (NDA), with data in H1/14 by our estimate. We certainly expect the data to be positive. At the same time, there is the chance that a single-arm mantle cell lymphoma study may read out positive data sufficiently robust to motivate the FDA to provide an accelerated approval. However, I don't think we'll see an application from either Johnson & Johnson or Pharmacyclics prior to the completion of those studies, which I believe are the earliest potential data points for approval regardless of strong results. There are a lot of existing therapies for these indications, and the FDA is somewhat bound by its regulations, which stipulate that when there are existing therapies, good clinical data must be presented before it considers approval of something new.
TLSR: What is the other best idea from the Wedbush list?
GW: We originally added Halozyme Therapeutics (HALO:NASDAQ) to our Best Ideas List in the latter half of last year. We thought the risk profile and opportunity were attractive. The company has a partnership with Roche Holding AG (RHHBY:OTCQX), one of the largest pharmaceutical companies in the world, for multiple injectable protein therapeutics, as well as its own proprietary programs. There have been some ups and downs in the stock, but we have conviction that both the underlying business and the fundamentals of the technology are strong. We continue to recommend the stock to our clients, believing that Roche's Herceptin (trastuzumab) will have a fairly rapid transition outside the U.S. for the subcutaneous route of administration that is facilitated by Halozyme's Enhanze techno logy.
We also have a very significant focus on one of Halozyme's in-house programs, which improves the predictability of both timing and potency of insulin's activity when delivered via a subcutaneous pump. We are confident the company will be on a commercial footing in the U.S. with that technology in the first part of 2013. It's a fairly straightforward technology that's had a few bumps in the road, but we are confident that the fundamentals are going to drive the stock going forward.
TLSR: HALO's technology has led to the advancement of a couple of products that have nearly made it through major regulatory decisions. One is Herceptin for HER2-positive breast cancer patients, yet the stock has been very weak. It's down 33% over the past four weeks. Why has it been weak?
GW: The first product expected to be approved using the Enhanze technology was Baxter International Inc.'s (BAX:NYSE) HyQ (immune globulin + Halozyme's rHuPH20 [recombinant human hyaluronidase] enzyme). Some non-neutralizing antibodies to the active ingredient that facilitates the subcutaneous route of administration with hyaluronidase were observed. As a result, the FDA indicated to the sponsor, Baxter, that it was likely to receive a complete response letter instead of an approval, and that it would need to do more work to understand if this autoimmune observation, which was not clinically significant, was potentially troublesome. The Street is always concerned when the FDA raises a potential safety issue. But we note that there was no change to the Hylenex (hyaluronidase) label, and no warning letter associated with what is an already-approved product. Hyaluronidase is approved to facilitate the absorption and distribution of drugs del ivered subcutaneously, and that continues to be the labeled indication for the enzyme on its own.
TLSR: Will approval of Herceptin support the rest of the pipeline? Will it prove the concept of the platform?
GW: Yes. A regulatory success will certainly be well respected by the marketplace and viewed as a significant positive. I also believe the income statement is going to be the driver for value creation for Halozyme starting in 2013 with its commercial efforts in the insulin pump setting.
TLSR: Are you playing this as a turnaround story?
GW: Well, it is now. It wasn't when we put it on our Best Ideas List. But we believe we understand the issues and the opportunities. The Street is more focused on regulatory issues right now and needs to look more at what the opportunity is.
TLSR: What is your next idea?
GW: Endocyte (ECYT:NASDAQ) is a really interesting company. It has been observed that solid tumors and activated macrophages often express a folic acid transporter, and that unlike the folic acid channel, this can transport folic acid conjugated to a drug into the cell. Endocyte has proven it can trick advanced ovarian cancer cells into pumping a toxic chemotherapeutic into themselves via this transporter, and thus delay disease progression. The results were sufficiently compelling to convince Merck & Co. Inc. (MRK:NYSE) to enter a co-development and commercialization partnership. Vintafolide (EC145) is a small molecule, and because of that, some studies have estimated a 30,000–50,000-fold improvement in penetration in solid tumors. And it is possible, using a radiolabele d version of the product, to image patients and identify those whose tumors might best be addressed with a folic acid-targeted chemotherapeutic. The ability to identify patients who might most benefit is an important part of the technology.
Because strong results were shown in the company's randomized phase 2 study in women with advanced ovarian cancer, European regulatory authorities have indicated that they would be receptive to a filing for accelerated approval in Europe. We expect that to occur in Q4/12, with a new treatment for women with advanced ovarian cancer on the marketplace in the early part of 2014.
TLSR: How big can vintafolide be if it is limited to just the ovarian cancer indication?
GW: It would easily bring in several hundred million dollars in Europe, and there is a similar market opportunity in the U.S.
TLSR: Does approval in the U.S. and Europe triple Endocyte's market valuation?
GW: It is presently trading at roughly one time the potential sales it could achieve in Europe. The overexpression of folic acid transporters is a feature found in a variety of solid tumors, including those in lung cancer, which is one of the bigger problems we face. We are looking at a targeted therapy that could easily have billions of dollars of revenue.
TLSR: What is the next inflection point for Endocyte? What catalyst is going to drive this stock?
GW: The stock will likely appreciate in anticipation of a positive European regulatory decision in the early part of 2014, or late 2013. But we are focused on a number of potential catalysts in 2013.
Specific to vintafolide, data from a randomized lung cancer study could be available in 2013. That would be very interesting to investors. In addition, as a result of the substantial cash payment that Endocyte received in the deal with Merck, it has the resources to drive three different programs into the clinic—another chemotherapeutic targeted with folic acid, an inflammation drug that targets activated macrophages using folic acid and, lastly, a promising treatment for polycystic kidney disease that focuses treatment to the cysts in kidneys of these patients. The company is going to have a dramatically expanding pipeline with a targeted small-molecule therapeutic agent, and will be approaching potential commercialization of that agent in the latter half of the year. Those are the catalysts, and I believe Endocyte is going to see its stock appreciate very significantly.
TLSR: Is vintafolide partnered with Merck for both non-small cell lung cancer and for advanced ovarian cancer?
GW: Yes. The global opportunity for the drug is partnered with Merck.
TLSR: How many points does Endocyte give away to Merck?
GW: It is 50/50.
TLSR: This pipeline looks very deep, but I'm sure the market is not giving any value to the company's other candidates whatsoever.
GW: That's right. The company has $200 million-plus in cash, and it is not even trading at two times cash. Based upon my conversations with investors, I think it is becoming a better-known story.
TLSR: Your next pick?
GW: I would focus investors on Anacor (ANAC:NASDAQ), a platform-chemistry company. It utilizes boron-based organic molecules to create new drugs. It is appropriately conservative in its approach. Boron-based molecules are fairly reactive. It started by making topical drugs. The main indication of the company's lead drug is on onychomycosis—toenail fungus. Phase 3 data for its first of two phase 3 studies are expected in the second week of January 2013, and the next is expected six weeks later. The drug is tavaborole (AN2690), and it is well tolerated by patients. We know it gets through the toenail. I think the marketplace is ready for a safe, effective, topical treatment for this dermatologic indication.
TLSR: What's your next idea?
GW: Novavax Inc. (NVAX:NASDAQ) has a very robust and interesting biologic manufacturing capability. It uses its expression system to manufacture virus-like particles to make vaccines, and has significant government support for both pandemic and seasonal flu vaccines. Recently, the company has shown a good result for treatment of a respiratory syncytial virus (RSV), one of the last significant pathogens that we don't have a vaccine for. This product would protect elderly folks, neonates (newborns) and young children against the virus. There is a strong chance that the company will enter into a significant global partnership for development of an RSV vaccine this year. That, combined with the opportunity it has in flu vaccine development, is very interesting. A lot of investor attention is being paid to Novavax.
TLSR: This sounds like the kind of company that could receive nondilutive capital from governments. Has Novavax been able to finance itself with grants from European or North American governments?
GW: Yes. The U.S. government is supporting the company through a contract in excess of $100 million to advance development of both pandemic and seasonal flu vaccines. The money will support the creation of manufacturing infrastructure and clinical regulatory work on the product. The technology allows for very rapid production of the vaccine, which will help in the event of a global health issue.
TLSR: Rapid production is the real value driver here, isn't it?
GW: Yes. Historically, very significant mortality has been associated with pandemic flu. The U.S. government places a very high priority on protecting the population from another potential pandemic.
TLSR: You follow Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX). I note that you rate it Outperform.
GW: Absolutely. We're expecting interim progression-free survival data very soon from the head-and-neck cancer study. Oncolytics is developing a very interesting idea with regard to cancer treatment, using a virus to treat a disease that is uniquely susceptible to viral infection.
Obviously, there are limitations to the continuous treatment of a patient with a virus. The human body oftentimes responds by an immune response that inactivates the product. But Oncolytics' reovirus (Reolysin) doesn't appear to elicit the type of robust response to this virus and repeated treatments are possible. It has shown the ability to infect tumors broadly throughout the body, and multiple tumor types are potentially susceptible to this approach. In addition to potentially killing tumors via the virus reproducing in cells and lysing (pretty much exploding them), the viral antigens can stimulate an immune response. The damage done to the cells by the viral infection can be sufficient to resensitize them to radiation and chemotherapy. Fortunately, there are no overlapping side effects with the most commonly used cancer treatments—radiation and chemotherapy—so this is, potentially, a broadly useful treatment.
TLSR: I wonder why the company started with such a tough indication. Squamous cell carcinoma of the head and neck is very difficult to deal with, yet many different oncology indications may be susceptible to the reovirus. Is the company targeting an unmet need?
GW: Yes. If I recall correctly, all oncolytic virus companies started out using intratumoral injections. Head and neck tumors are, obviously, quite accessible via that approach, with strong evidence of the potential for efficacy. The study design for its ongoing phase 3 is very similar to that of Eli Lilly and Co.'s (LLY:NYSE) Erbitux (cetuximab)?. In fact, the reovirus study is a carbon copy of the Erbitux phase 3 study, and is being managed in a very similar way. The route to registration is well worn using this development strategy.
The interim analysis data, which we are expecting shortly (likely in August), will look at progression-free survival results from the first 60–80 patients. This will help assess whether there are reasons to be optimistic about success in overall survival rates, and how many patients it might take to get to that endpoint. They will be the first randomized, controlled data in a solid-tumor setting for an intravenous oncolytic virus delivery. It is a very important data point for the company. Because of the broad opportunity in front of the drug, we think investors would be well served to pay attention to the results. Even if the results are positive and the stock moves up, the big picture remains compelling. We are counseling investors to keep their eyes open.
TLSR: Oncolytics has been weak. It is down 39% over the past six months. In this first randomized data, the drug will be measured against a control arm, and definitive evidence of efficacy could be demonstrated. Is the weakness because Oncolytics is a one-drug company? Why has no faith been given to Reolysin?
GW: There has been a slight delay in the readout (presentation of data), and concerns that this delay is due to a problem. I don't think that is right. The company has a completely new and novel way of treating cancer, and I think there is some skepticism about its potential viability.
TLSR: You don't follow Addex Therapeutics (ADXN:SIX; ADDXF:OTCBB) formally, but the company presented at your conference. Are you familiar with it?
GW: Sure. We had a chance to catch up with our friends from Addex at the conference. I don't think the company has a strong U.S. following, despite what we believe are very compelling data for its metabotropic glutamate receptor 5 (mGluR5) inhibitor, dipraglurant. The company is confident that it will find a partner to develop the product, first in an indication for Parkinson's disease levodopa-induced dyskinesia (PD-LID). With support and validation, investors will come to appreciate the opportunities for the drug in the PD-LID indication. Addex is an interesting, undiscovered company, and is undervalued perhaps because of the stock's low trading volume, Swiss stock exchange listing, and the relatively modest number of patients treated in its dipraglurant clinical studies.
TLSR: Are any prominent companies working on allosteric modulators, like Addex is?
GW: I am not familiar with any other companies pursuing these as a general approach.
TLSR: That gives us some hint as to why this is an undiscovered technology from the market's point of view.
GW: Addex has had a lot of programs, some of which haven't succeeded. Making allosteric modulators is difficult—it is about finding the right drug for the right indication. I certainly think dipraglurant hits that mark. We shall see. With a partnership, I think Addex will be a different story.
TLSR: I find it interesting that allosteric modulators don't compete with receptors that are bound by the ligands in the organism on a normal basis. It opens up all kinds of opportunities.
GW: Yes, absolutely. I think we should let the body decide what notes to play, and maybe just tune the piano; make it a little louder or quieter when appropriate. We certainly have a large body of data for the type of unfavorable effects that can come from drugs that act in the central nervous system that go knocking on a lot of receptors all the time. The trick has been specificity. I think some folks at Addex are getting to the heart of that issue as well.
TLSR: Thank you, Greg. This has been fun.
GW: Any time you want to talk about stocks, I'm always here.
Greg Wade earned both an undergraduate honors degree in medical biophysics and doctorate in physiology from the University of Western Ontario in London, Canada. He has worked on the sellside since early in 2000, first at Pacific Growth Equities and subsequently at Wedbush PacGrow LifeSciences, where he was promoted to managing director in 2011. Greg's coverage of emerging biopharmaceutical companies is supported by his analyst team members David Nierengarten and Chris Marai.
Want to read more exclusive Life Sciences Report interviews like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see a list of recent interviews with industry analysts and commentators, visit our Exclusive Interviews page.
DISCLOSURE: 1) George S. Mack of The Life Sciences Report conducted this interview. He personally and/or his family own shares of the following companies mentioned in this interview: None. 2) The following companies mentioned in the interview are sponsors of The Life Sciences Report: Oncolytics Biotech Inc., Addex Therapeutics. Merck & Co. Inc. and Johnson & Johnson are not affiliated with Streetwise Reports. Streetwise Reports does not accept stock in exchange for services. Interviews are edited for clarity. 3) Greg Wade: I personally and/or my family own shares of the following companies mentioned in this interview: Pharmacyclics Inc. I personally and/or my family am paid by the following companies mentioned in this interview: None. I was not paid by Streetwise Reports for participating in this interview.
Streetwise – The Life Sciences Report is Copyright © 2012 by Streetwise Reports LLC. All rights are reserved. Streetwise Reports LLC hereby grants an unrestricted license to use or disseminate this copyrighted material (i) only in whole (and always including this disclaimer), but (ii) never in part.
The Life Sciences Report does not render general or specific investment advice and does not endorse or recommend the business, products, services or securities of any industry or company mentioned in this report.
From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles on the site, may have a long or short position in securities mentioned and may make purchases and/or sales of those securities in the open market or otherwise.
Streetwise Reports LLC does not guarantee the accuracy or thoroughness of the information reported.
Streetwise Reports LLC receives a fee from companies that are listed on the home page in the In This Issue section. Their sponsor pages may be considered advertising for the purposes of 18 U.S.C. 1734.
Participating companies provide the logos used in The Life Sciences Report. These logos are trademarks and are the property of the individual companies.
101 Second St., Suite 110 Petaluma, CA 94952
Tel.: (707) 981-8204 Fax: (707) 981-8998 Email: firstname.lastname@example.com


text:
James Dean: Forever Young documents the brief but memorable career of the now iconic James Dean. The film focuses much attention on his early work for television, and utilizes a variety of archival footage in order to ale the tale of the young man who gained immortality with only three feature films to his credit. ~ Perry Seibert, Rovi
All James Dean: Forever Young cast + crew photos


text:
An Interview with Richard Dawkins on His New Memoir, Evolution and God.
"British evolutionary biologist Richard Dawkins was catapulted to fame in 1976 with his first book, "The Selfish Gene." It revolutionized Charles Darwin's theory of evolution with the idea that genes are the keys to natural selection. Dawkins was the first professor for public understanding of science at Oxford University. And he is one of the world's most outspoken atheists, author of "The God Delusion." His latest book is the first volume of a two-part memoir titled An Appetite for Wonder: The Making of a Scientist. It covers his childhood in Africa through his mid-30s."
The audio interview on NPR can be heard HERE
The audio interview on NPR can be heard HERE


text:
GoldfingerFrom the opening bomb blast outside a steamy nightclub to a last-minute escape from the U.S. presidents personal jet this exhilarating adventure pits 007 against a maniacal villain bent on destroying all the gold in Fort Knox - and obliterating the worlds economy.The Man With The Golden GunWhile trying to recover a priceless Solex Agitator energy converter Agent 007 finds himself in a heart-stopping duel to the death against world-renowned assassin Francisco Scaramanga whose weapon of choice is a distinctive gold pistol.GoldeneyeBond races to Russia in search of the stolen access code for an awesome space-based weapon of mass destruction and squares off against his former compatriot Alec Trevelyan a.k.a. 006 a mastermind who can anticipate Bonds every move. Special Features: Goldfinger Sean Connery from the set of Goldfinger screen tests On tour with the Aston Martin DB-5 Honor Blackman open-ended interview Interactive guide into the world of Goldfinger Audio commentary featuring director Guy Hamilton Audio commentary featuring cast and crew The making of Goldfinger The Goldfinger phenomenon Original publicity featurette Original trailer TV spots photo gallery and radio communications The Man With the Golden Gun Newly recorded audio commentary featuring Sir Roger Moore Roger Moore and Herve Villechaize - the Russell Harty show On location with The Man With the Golden Gun Guy Hamilton: the director speaks Girls fighting American thrill show stunt film The road to Bond: stunt co-ordinator W.J. Milligan Jr. Interactive guide into the world of The Man With the Golden Gun Audio commentary featuring Guy Hamilton and members of the cast and crew Inside The Man With the Golden Gun - an original documentary Double-O stuntmen: a look at the greatest stunts and stunt performers in the B Original trailers TV spots photo gallery and radio communications. Goldeneye Deleted scenes with introduction by director Martin Campbell Directing Bond: the Martin chronicles Building a better Bond: pre-production featurette The return of Bond - the start of production press event Driven to Bond: Remy Julienne Anatomy of a stunt: tank versus Perrier Making it in small pictures: Derek Meddings On location with Peter Lamont Pre-title storyboard sequence with director Martin Campbell Interactive guide into the world of Goldeneye Audio commentary featuring Martin Campbell and Michael G. Wilson The world of 007 - original 1995 television special hosted by Elizabeth Hurley The Goldeneye video journal promotional featurette Goldeneye music video performed by Tina Turner Original trailers TV spots and photo gallery
Check stock and price


text:
News Archive
2nd Degree Murder Charges in Rockville Shooting Case
A Walker, Minnesota man has been charged with one count of second degree murder in the death of a Rockville man last Sunday.
The Stearns County Attorney's Office has charged 28-year-old Marcus Michael Barshaw in the shooting death of 30-year-old Jeffery Schultz. The Attorney's office says that preliminary autopsy results indicate that Schultz was shot six times, with possibly two additional fired rounds hitting Schultz's clothing.
According to the statement of probable cause, on Saturday night a woman was contacted by Barshaw via Facebook and asked to pick him up from Walker. When the woman arrived at his apartment Barshaw placed items in the trunk of her vehicle. The woman knows that he typically carried a firearm and would often put the firearm(s) in the trunk of her car. When they arrived in Rockville, she asked Barshaw to stay in the car as she went and talked to Schultz. Schultz did not want Barshaw at his residence and they got into an argument. Sometime after that Barshaw and the woman went into a recreational vehicle (RV) that was parked in the backyard and Barshaw was seen bringing two firearms into the RV. While they were in the RV Schultz approached the door and an argument between Schultz and Barshaw began. The woman then stepped out of the vehicle to talk to Schultz and then Barshaw stepped out of the RV holding the "bigger gun" and shot Schultz several times as he was trying to run way.
Barshaw was later found hiding in a nearby apartment building. He was then shot by a Stearns County deputy after he came out of the apartment holding what was believed to be an assault rifle and a pistol. Barshaw did not put down his weapons after a Sheriff's deputy ordered him to.
Barshaw is currently receiving medical treatment and remains in the custody of the Stearns County Sheriff's office. The Stearns County Attorney's office will schedule Barshaw's initial court date once he's has been released from the hospital. The investigation is still ongoing.
Latest News
St. Cloud Police Believe Missing Student Jesse Dady May Have Fallen Off Railroad Bridge
Investigative Files Into Wetterling Abduction To Be Released
Sports Schedule
Softball vs
Minot State University
Apr 01, 2017 - 1:00 -
Baseball vs
Upper Iowa (Sports Stream)
Apr 01, 2017 - 2:00 -
Softball vs
Minot State University
Apr 01, 2017 - 3:00
Audio Feeds
Subscribe to what interests you. More information about podcasts and software.


text: Here's What Happens When 40,000 College Students Realize They Can E-Mail All 40,000 People at OnceCasey Chan11/27/12 7:40pmFiled to: WtfCollegeEmailNyuStudentsreply all133EditPromoteShare to KinjaToggle Conversation toolsGo to permalink NYU recently sent out a seemingly innocuous e-mail to all of its students asking them to opt for paperless forms. People in college get those kinds of e-mails all the time! But when one student decided to ask his mom if he should enable the paperless forms, he accidentally triggered a method that allowed him (and every other student) to reply all to all 39,979 students on the e-mail list. Which meant, any student could send an e-mail to every single student at NYU. And as things in college goes, things quickly got out of hand. Advertisement Apparently, the student, NYU sophomore Max Wiseltier, accidentally replied all to an archaic Listserve system that sent any reply to every single student. Typically, NYU would use a system called 'E-mail Direct' to handle mass emails. Those mass emails can't be replied all to and as such, are meant solely for one-way emailing. Some NYU departments, however, use the older ListManager program. NYU Local's tech editor, Ben Zweig, explains:Several NYU departments still rely on the older, discussion-based ListManager program, however. ListManager also sends mass emails, but allows discussions (in the form of reply-alls), unless the settings are adjusted, disabling group discussions and only permitting emails from admins.Here's a sample of some of the e-mails sent. It goes from happy Nic Cage pics to SHUT THE FUCK UP in no time. Thousands of e-mails were sent over the course of one night, so yeah, I can see how that would get annoying. Read the whole report at NYU Local and see more hilarious emails at BuzzFeed. [NYU Local via BuzzFeed]Reply133 repliesLeave a reply


text: Step into the Divaville Lounge on Sunday, March 27 as we pay tribute to the divine Sarah Vaughan! Vaughan's powerful voice and distinctive phrasing made her one of the most important jazz singers of the 20th century. In this tribute program, guest hosted by DJ Georg, we'll hear two hours of Sassy beginning with her very first recording in 1944, and ending with a track from her last full-length album in 1987. Along the way we'll hear Vaughan performing with Dizzy Gillespie, Miles Davis, Clifford Brown, Count Basie, Quincy Jones, Sergio Mendes and Milton Nascimento. Tune in for an afternoon of Sassy!


text:
By Raj Giri | January 17, 2013 | Comments |
Source: Kayfabe Wrestling Radio
"Even Steamboat, he's gone on record saying the one match he's never liked was losing to an Elvis impersonator. Well, you know, I look at it like this; listen 'Dragon', you could have lost it to a guy in a skirt blowing the bagpipes, or you could have lost it to a guy with a snake, or you could have lost it to Hulk Hogan, hey Brother with the 21-inch pythons, or you could have lost it to Brutus 'The Barber' Beefcake and he could have shaved your head. You know, to say something like that, it struck a little chord with me and he was not the most professional that night. If people go back and watch this match, you'll see I gave him about 90, or maybe 95 percent of the match was all his and let him shine and do all his stuff and by fluke and however it went down; we threw Jimmy Hart in the mix and Jimmy got hit and boom and this and I grab the rope, 1-2-3. And it was one of those things where I did everything to make this guy look good and make him be happy about it. After it was over and he back and we had return matches a couple of time, he was fine.
"You know, there's been other guys; if Tito was here right now, I'd tell him, I hope he's listening. Tito Santana; Oh, you've got to pull my feet, Jimmy Hart's gotta hit me with a megaphone, we've got to knock the referee down. Oh, come on, I took that flying burrito elbow and never said a word about it, 1-2-3. But when it come time for those guys to do the favor, it was like, 'Naw. Can we do this? Can we do that?' There was a couple of times that went on. Yeah, you know, I never ever said anything about any of it until that came up with the Macho Man thing, and it nothing to do with Randy; Randy and I talked about it. It was all about the television thing with 35 million people."
You can download and listen to the full interview at this link.
Got a news tip or correction? Send it to us by clicking here.
Author's link:
Fightline.com - Debut After Tonight's Impact >>
WrestlingInc.com is the largest independently owned wrestling website in the world (Source: Alexa).
Become a fan on Facebook, follow us (@WrestlingInc) on Twitter:
Follow @WrestlingInc


text:
Your Shopping Cart
> Maple Bacon Donut Shooter
Maple Bacon Donut Shooter
We bring you a liquid version of the popular Maple Bacon Donut.
It's a shorter version of a cocktail. Bacon in a shot glass!
5 oz. of Bacon Infused Vodka
5 oz. of Butterscotch Schnapps
5 oz. of Bailey's or Irish Cream
Teaspoon (or more) of Maple Syrup (Grade B or Dark Amber preferred)
Get a shot glass. First pour in the bacon infused vodka. Next, the Butterscotch Schnapps. Then add the Irish Cream. Finally, with the Maple Syrup, make sure you pour directly through the middle of the glass to ensure that the sides of the glass stay clean of syrup. Garnish with some bacon if you would like!
Recipe from www.BaconToday.com by Brianne Rivlin
100% Real Gourmet Bacon Superstore
Sizzlin' Hot Deals
New Items
The Bacon
Bacon Gift Bundles
Bacon of the Month Clubs
Bacon Sweets & Snacks
Bacon Pancakes
Bacon Beverages
Bacon Jerky™
Bacon Novelties & Gifts
Bacon Clothing
Bacon Seasonings & Condiments
Bacon Pet Treats
Ham & Sausage
Swine & Wine
Bacon Cookbooks
Why Not?
Bacon Gift Certificates
Greeting Cards & Announcements
Wholesale Products
Flash Player Needed


text: First Person Smash Bros. Is Just As Gruesome As You Might ThinkGergo Vas6/03/14 8:30amFiled to: smash broswatch thiskotaku corenintendo466EditPromoteShare to KinjaToggle Conversation toolsGo to permalink GIF Dodging and edge-hogging would be 100% more dramatic in Smash Bros. with a first-person view. YouTuber pipocaVFX gives us a sneak-peek featuring Link, the Master Hand and a scary third special someone at the end. Advertisement We're lucky that the clip is not from Super Smash Bros. Wii U. I just don't want to see Animal Crossing's Villager coming at me with those eyes in first person mode.First Person Super Smash Bros. [YouTube]To contact the author of this post, write to: email@example.com repliesLeave a reply


text:
Highly detailed figure with loads of accessories to recreate your favourite Pirates of the Caribbean scenes. Captain Jazz has the Prison Wagon and a Rifle reveal the zombie within and make Jack look like a zombie. Please Note: This item is part of an assortment and we cannot guarantee which one you will receive.
Check stock and price


text:
Are Teeth Whitening Strips Safe?
As an alternative to costly teeth whitening procedures at the dentist's office, many people have turned to at-home dental whitening strips to achieve a bright, celebrity-style smile in a shorter time frame. Although the efficiency of at-home whitening strips has its own share of debate, most people are concerned about the safety of the products that promise a whiter smile without the higher price.
What might give you a hint about the safety as well as the efficacy of over-the-counter dental whitening strips is an understanding of how they work. According to the American Dental Association, teeth whitening strips are made from polyethylene and are coated with a chemical called carbamide, more commonly known as hydrogen peroxide.
As the hydrogen peroxide is broken down, oxygen comes in contact with the enamel and bleaches any discoloration of the tooth. The process does not alter the structure of the tooth in any way, but does have the potential to weaken enamel if used too frequently.
A 2008 study conducted by researchers at The Procter & Gamble Company, examined the safety of 12 months continuous use of 6 percent hydrogen peroxide whitening strips, using a placebo control group to eliminate error. The study randomly assigned 80 adults to receive one of two treatments: whitening strips coated with 6 percent hydrogen peroxide or placebo strips.
Each group wore the strips for 5 minutes, every day, for a 12-month period. The researchers collected evidence on the safety of the treatment through oral status interviews and oral examinations at various points in the 12-month process.
The findings revealed that tooth sensitivity was reported by 10 percent of participants in the group given the hydrogen peroxide strips and 5 percent of the participants in the placebo group. There were no reports of oral irritation in the hydrogen peroxide group and approximately 3 percent reported irritation from the placebo group; and the occurrence of observed oral irritation was similar between the two groups.
Based upon these results, researches concluded that the use of hydrogen peroxide whitening strips over a 12-month period revealed a similar safety profile as the use of placebo strips.
In other words, the study found that dental whitening strips are almost as safe for the teeth as abstaining from using whitening strips at all. However, the study also revealed that continued use can lead to tooth sensitivity and minor irritation and users should consult their Boston dentists before prolonged use.


text:
- Step One:
Learn and follow established accessibility guidelines and standards. The W3C Web Content Accessibility Guidelines 2.0 , level AA, serve as the Web accessibility standards for the University of Minnesota. -
Step Two:
Best practice is to validate your HTML and CSS code to be sure that it is error-free and complies with W3C standards. It is important to use the HTML validator to create documents that are parsible so that user agents, including assistive technologies, can accurately interpret and parse content. Some tools that can help:- W3C HTML Validator - Checks HTML documents for conformance to W3C HTML recommendations and other W3C standards.
- W3C CSS Validation Service - Checks Cascading Style Sheets for conformance to W3C standards.
Step Three:
Evaluate the pages in your site with accessibility tools. Here are some tools that can help:- WAVE - Shows your original page, with icons and indicators revealing accessibility problems and features. It requires a basic understanding of accessibility but it also provides explanations of what things mean and teaches along the way.
- HiSoftware Compliance Sheriff - Disability Services has purchased HiSoftware Compliance Sheriff application site license for use by the University of Minnesota Web community. The software aids in identifying accessibility issues, provides information on the importance of accessibility features, provides resources for understanding and resolving accessibility issues, and highlights accessibility issues in both the rendered view and the source code.
- A graphical user interface (GUI) browser (such as
Firefox, Internet Explorer or Chrome)
- These can be helpful for accessibility evaluation
also. Examine your pages while adjusting the browser
- Turn off images then make sure that the information is presented in an appropriate sequence relative to the visual presentation on the GUI site.
- Turn off the sound then make sure audio content is still available through text equivalents.
- Change the font size (larger and smaller) in the browser, and observe whether the page is still readable.
- Change the display color to black and white (or print out the page on a black and white printer) and observe whether color contrast is adequate.
- Put away the mouse and tab through the links and form controls on a page. Make sure that you can access all links and form controls, that links have a visible focus indicator, and that they clearly indicate what they lead to.
- Web Developer Extension for Firefox - It adds a menu and a toolbar to the browser with numerous web developer tools.
- Luminosity Contrast Ratio Main Colour Contrast Analyser - Tools by Gez Lemon for evaluating color contrast. These are useful in that you don't need to make a judgment call to decide which colors to examine, and you can choose between the luminosity algorithm suggested for WCAG 2, the original AERT algorithm suggested for WCAG 1, or both.


text:
WELCOME to "VINTAGE FINERY" COSTUMES & COMPLETE BRIDAL. Owned by collector: LINDA MITCHELL-STORER.
(linda_vfinery@yahoo) Call(207)356-9560 You can also find Linda and her shop on Facebook.
Hats & Accessories
"Vintage Finery - Costumes & Complete Bridal" has thousands....of vintage to new hats, gloves and accessories for sale or rent! It's the best place to shop, with bargain prices!
Comments (0) | Add a Comment


text:
Before you ever get to the stage where you plan your strategy, you must already be armed with your personal cheatsheet of player values and the budget you will use (or not and probably regret). Once you are comfortable with those, then and only then should you move to the most important part of the equation - how will you turn that knowledge and those bidding dollars into a killer auction team?
You have three basic choices to make and each produces very different sorts of teams. Your decision on which one to pursue should depend on your comfort level with the team you end up. This is a critical decision because it will allow you to control your destiny for the season. You need to choose before you show up and stick with the strategy or you will end up being controlled by the auction and end up with a team that is allowed you rather than one you created.
Remember - making no decision is a decision itself and never the best one.
Go Big - Going big means buying at least two if not three of the superstars. You know, going in, you want to snag Priest Holmes, Deuce McAllister and Randy Moss. And you can, possibly, do this. You can certainly get Holmes and McAllister. And like cherry vodka, it feels good in the early stages. I mean "whoa, baby! You single? I love you guys" kind of good.
Upside - You get superstars! The main tenet in fantasy football is that you have to score better than the league's weekly average in order to win consistently. This is a great way to do just that. As long as you are able to fill in the rest of the roster with at least middle of the road players, you will likely win most games. Get a few sleepers to come through for you and you are sitting pretty. Often the league champs come from teams that take this risk. Often the cellar dwellers do this as well. Those power hitters only need mid-level talent to pull their weight and you will contend and land a sleeper or two and you'll look like the genius of the auction.
Downside - You are one injury or star-turned dud from being the league dog. Just like the NFL, you have to make it unscathed all season and have to have those stars perform in relation to their paycheck. What if you had paid the cash for Boldin or Boston already? Marcel Shipp? Or the next dozen players that will be coming on the injury report this season. Plus you have to know that about half those top players do not meet expectations too. Do ya feel lucky? General Armstrong Custer was known to be very confident, arrogant even, up until that whole Little Big Horn thing.
Draft Equivalent - This is like getting two #1 picks, plus maybe a #3 pick and then the rest of the team is from round eight or deeper.
Go Wide - This plan is the most common. It entails normally getting one top stud player, one really good player, a few good ones and then backups and filler. This strategy allows you to target individual players you really want (within reason) and be flexible to pick up good values. This is a natural plan for someone who is confident in all his valuations of players and knows when someone is a good value and when he is not. This person bids - a lot. A very active player since he will be involved in establishing the bid value of most players.
Upside - You do not get killed by one injury and produce solid numbers as long as overall your team stays intact. While you normally have few stars, you do not have many duds. It is a great way to remain competitive at all times. No one ever laughs at this strategy. It can be played very well with an astute bidder that can use a game plan mixed with value picks to produce a solid team with most all money spent on the top half of their roster with an eye to filling out those starter spots the best possible. This is safe and effective. This is the standard formation from those who are used to picking players, one per round, all their lives. This is oten a team owner in one of their first auctions but who is comfortable with player value.
Downside - This is most often a ticket to ending up at about .500 on the year. These type teams normally fill the final standings between the 3rd best and 3rd worst teams. No stars and no come-through sleepers normally. The biggest qualifier to how well the team does is the fortunes of the two costliest players and how the hit for the season. If they meet expectations and remain healthy, should produce a team in the upper half of the standings but likely not the top spot.
Draft Equivalent - Focusing the majority of a cap towards the starting slots only with far less for back-ups will produce a traditional looking fantasy team. They will usually have about one player that would have been picked from each round of a draft. This is applying a draft strategy to an auction.
Go Deep - This strategy is not for the feint of heart. It entails waiting, normally for the first 40 players to be taken before finally winning a bid. There are no obvious superstars but no duds either. Your picks are all upside players with an eye for getting as many sleepers as possible and hoping to land a full set of starters out of them. This is the guy that waits patiently while everyone takes all the big-name players. And then, about 40 or 50 players into the auction he will rule because he has all the cash to take any player he wants for a good while.
Upside - No injury, or even a couple injuries, really hurt this team. It is has solid, maybe not spectacular yet, talent and has the best depth and likely the best trading position as well. This plan also contributes it share of championships. This is a plan that maximizes player value and allows the greatest "working" of an auction as it unfolds.
Downside - You have to manage this team like a mad man. Trade, free agency and always tracking all your players to see who is stepping up and who needs to be shipped out. Unless you land several sleeper types, this is also a ticket to the standing's cellar. This takes the most amount of skill and a nice dose of luck does not hurt here either. You have to know when to pull the trigger and when to put the gun down. Can end up facing another team owner with the same strategy and become locked into bidding wars that escalate the value of a deep player far above his relative value because you've let the tiers drain until your options become limited. Watching those top players all fly off for values well above your budget is painful and scary.
Draft Equivalent - Think of it this way, it is like having all your picks come between the fourth and tenth round of a normal draft. Could you field a good team like this? Think you can create a great one?
Armed with knowledge and prepared for anything, you need to decide if you want to go big, wide or deep. And you have to know that before the auction starts. You'll see soon enough which of the three plans other teams will follow. Assess the risk and make that play. Knowing player values, tiers and your budget will allow you to see the value picks that make a big difference. Every strategy of bidding had its own unique upside and downside, it all points back to being able to value the players correctly before the auction starts.
Auction neophytes often like to "Go Big" since they are getting their first opportunity to select from all super stud players unlike in a traditional draft. The most common approach will be the "Go Wide" which is safe, effective and usually results in a solid yet unspectacular team. Many of the "Go Wide" bidders have not fully come to understand the difference between an auction and a draft. Lastly, the "Go Deep" crowd is the smallest and invariably involves the team owners that are the most knowledgeable (ask them, they will likely gladly confirm it). It is the riskiest strategy but one that best addresses the hunt for player value in an auction.
There is no single method that ensures success because each should be matched to the bidder's strengths and weaknesses. Decide what suits you best and devise your game plan accordingly. After the first 30 or so players are awarded, you will know what style each bidder is using. And the more astute will see your plan as well – you do have a plan, right?


text:
The world premiere of Ang Lee's "The Life of Pi" (November 21) will open the upcoming 50th New York Film Festival (September 28 – October 14), the first 3-D film to do so. (Martin Scorsese's "Hugo" played as a 3-D work-in-progress last year.) The NYFF has already announced its closing night film, Paramount's "Flight," directed by Robert Zemeckis and starring Denzel Washington, which also marks a mainstream booking for the often high-minded Fest. Of the 25 or so films in the main program, the galas are often more accessible fare.
Lee also screened Cannes entry "Crouching Tiger, Hidden Dragon" 12 years ago to close the fest, and opened it with "The Ice Storm" in 1997. Thus Lee joins master auteurs Robert Altman, Pedro Almodóvar and François Truffaut as the only directors to have opened the fest more than once.
Lee wowed exhibitors with footage from the film at CinemaCon in Las Vegas in April, as distributor Twentieth Century Fox made it clear that they had high holiday and awards expectations for the film. Based on the global bestseller (7 million copies sold), the film boasts the right elements: globally popular literary source; heart-warming family story from an A-list Oscar-winning director ("Brokeback Mountain"); and epic VFX. Technology finally made the film possible. The CinemaCon "Life of Pi" footage looked stunning: a ship in a violent storm, a zebra leaping into a lifeboat, a shot of Pi Patel underwater watching the ship holding his family sinking into the depths, his power struggles with a Bengal tiger on the boat, and a scene with thousands of flying silver fish. Lee also participated in a rousing conversation with Martin Scorsese about how to shoot in 3-D.
In 2009, the Film Society of Lincoln Center conducted a complete retrospective of Lee's work at the Walter Reade Theater. Other opening night selections include Luis Bunuel's "The Exterminating Angel," Akira Kurosawa's "Ran," Almodovar's "Women on the Verge of a Nervous Breakdown," Mike Leigh's "Secrets and Lies," Stephen Frear's "The Queen," and David Fincher's "The Social Network."
"'Life of Pi' is a perfect combination of technological innovation and a strong artistic vision," says Richard Peña, Selection Committee Chair & Program Director, The Film Society of Lincoln Center. "Ang Lee has managed to make a deeply moving, engrossing work that will delight audiences as much as it will astonish them."
See trailer below.


text:
"We just plow through it all. We put the blinders on and just go. We don't slow down for trends or what's not hip anymore. We just stay true to ourselves."
James Hetfield
"Creatures of a very particular making, we need to know the cultural blinders that narrow our world view as well as the psychological blinders that narrow our view of our personal experience."
Christina Baldwin
"We must reinvent a future free of blinders so that we can choose from real options."
David Suzuki
"We're looking at it that we're still one team. We want to put on blinders for now."
Joe Walsh
"They have blinders on. They want a state court to decide their case, and they can't have a state court decide their case without overruling 200 years of United States Supreme Court precedents."
Howard Dickstein
"Those without the fearlessness to seek the truth will cling tenaciously to what is true for them, regardless of the degree of absurdity."
Rain Bojangles
"He ran a blinder. He jumped great. Noel gave him a great ride and he just weakened up the run-in, but he ran his heart out. We will leave him for 10 days and see how he is but he has a few entries and he could run again before the end of the season."
Frank Berry


text:
All Sites
Check-out: 11:00 am
"We want our customers to feel that our campground is their home away from home!"
We are certainly used to staying busy. After four years in the Air Force, Rick had a 25-year career with the North Naples Fire Department in Naples, FL. Debra worked as a paramedic for Collier County EMS in Naples and as anoffice manager for a medical transcription service."We Both enjoyed camping as children and continued that love of camping while raising our six children. They are all now grown and they still love to camp," says Rick. Two of Rick and Debra's sons are joining them at the campground, as there is enough work for everyone!


text:
Hello, I use onBeforeInsert in my table_edit.php to generate a value which should be added to the database (will come from another subsystem so it's not available during the form input). currently i do the following but thing there is a better solution . Code: function onBeforeInsert() { global $app $app->tform->errorMessage = myfunction($_POST) ; $this->dataRecord['value'] = $_SESSION['value'] ; unset ($_SESSION['value']) ; } Code: myfunction($_VAR) { global $_SESSION ; ... if (ok) $_SESSION['value'] = "foo"; (else) return "error foo :-(" ; }
May you describe a bit more what you try to do. ISPConfig has various methods to validate and filter user input incl. custom validators and custom datasources for values. A custom validator or custom datasource is a php class which can handle nearly any kind of value and the validators and datasources are just configured in the tform file, there is no overriding of onBeforeInsert nescessary then.
I have a form with Value A and B What i tried to find out was how to : Entering Value A into a form --> submit the form --> use onBeforeInsert function in myform_edit.php to generate Value B and store this into the table. So Value B is not entered by the user but generate by ispconfig. I found that i simply can use $page->dataRecord['B'] = $result['object'] ; to fill B.
Yes, thats correct. If B is defined in the tform file as table field, you can set B in dataRecord in any event function that gets executed before the insert or update happens.


text:
Antibes Luxe Sectional Armless Cushion
- No Longer Available -
Our lofty, zippered and poly-filled cushions come in a choice of premium, all-seasons Perennials® or Sunbrella® fabrics. Both Perennials and Sunbrella fabrics are easy-care and weather-friendly, resisting mildew, stains and fading.
Show Details +
- Seat: 25½"W x 27"D x 4¾"H
- Backs: 25½"W x 4¾"D x 20"H
Cushions shown in linen Sunbrella® Canvas.


text:
- Home
- Products & Solutions
Network services
- Access choices
- Application performance management
- Internet services
- IP address management
- Managed network services
- Virtual Private Network Services
- Network services solutions
- Industries
- Why BT
Analyst reports and recognition
Our position and recognition in published analyst reports.
A sustainable and responsible business leader
We believe in the power of communication to make a better world
We are proud that our work is recognized time and again by customers, analysts and professional organizations
BT in the Americas
Our company overview: how we're bringing it all together around the world
Case studies
Who we've helped, and how. Learn how organizations just like yours get better when they work with us.
Join us to explore fresh ideas
Let's Talk Point of View
Explore and debate the big issues with us as we bring together the latest insight on the hottest IT trends.
From press releases to local news
Our Innovation
Great thinking from across the company
Our showcases
Our range of showcases offers you an online or face-to-face insight into our portfolio and its capabilities.
Our technology vision – the 'Cloud of Clouds'
Our role as the Cloud Services Integrator
Who we work with around the world
Service from BT
How we put our customers first
The leadership team
Meet Luis Alvarez, CEO, BT Global Services and the rest of his leadership team.
- Let's Talk
Watch our videos on YouTube
- My Account
BT cloud-based solution sees collaboration sweep through RSA global organisation
Worldwide social media-wise workstyle
Responsible for communications, brand, and social media, it was only natural Jenny Burns should take the lead in a digital transformation programme sweeping through RSA like wildfire. Called The Big Upgrade, it uses a BT One Cloud platform hosting Microsoft Outlook, Skype for Business, and SharePoint throughout the RSA world.
Freed to do their jobs in fundamentally different ways, RSA people can operate in three distinct workstyles – roamers, hoppers or residents. They collaborate globally with customers, partners and each other. Desktop video conferencing is just one of the technologies catching on as the new cool.
Costs have fallen and we're getting competitive advantage through better customer service and faster time to market for new products."
- Jenny Burns, Communications, Brand and Social Media Director, RSA
RSA and The Big Upgrade
Watch how latest cloud technology from BT is keeping financial services leader RSA ahead of the global collaboration curve.
Fast facts
- RSA vision is for its 19,000 people to be able to work together under one virtual roof
- BT solution is seeing social media-style collaboration sweep through the RSA organisation
- Staff now operate in three distinct workstyles – roamers, hoppers, and residents
- Trailblazers are championing new ways of working; email has already reduced by 30 per cent
Making today's workforce flourish
Rapidly displacing an age-group whose shared experience is based in a world of rigid desktop-embedded business processes, Generation Y demands mobility and adaptability. To flourish, they need the right tools and technologies. RSA recognised that from the start. Across all industry sectors, others are waking up to that new flexible working reality too.
With the BT cloud of clouds vision
The BT One Cloud solution adopted by RSA is a component of the BT cloud of clouds vision. Aimed at helping large organisations connect easily and securely to the applications and data they need, this new network-centric model is agnostic of where they're hosted.
Getting everything working together
Cloud of clouds is a practical route into cloud computing that meets the need for choice, flexibility and compliance from people who know how to make it all work together. It's already supported by more than 20 cloud-enabled facilities across five continents with a further 30 cloud service provider data centres connected.
View the full case study on SlideShare


text:
Give us a call to get our secret deals 1-800-468-3578
Property Location
With a stay at Lakeem Suites Ikoyi in Lagos (Ikoyi), you'll be minutes from African Artists' Foundation and close to Ikoyi Golf Club. This hotel is within close proximity of Lagos Motor Boat Club and Nigerian National Museum.
Make yourself at home in one of the 27 air-conditioned rooms featuring refrigerators and flat-screen televisions. Complimentary wireless Internet access keeps you connected, and cable programming is available for your entertainment. Private bathrooms with showers feature complimentary toiletries and hair dryers. Conveniences include phones, as well as safes and desks.
Make use of convenient amenities, which include complimentary wireless Internet access and concierge services.
Satisfy your appetite at the hotel's restaurant, which serves breakfast, lunch, and dinner, or stay in and take advantage of 24-hour room service. Quench your thirst with your favorite drink at a bar/lounge.
Business, Other Amenities
Featured amenities include dry cleaning/laundry services, a 24-hour front desk, and luggage storage. Free self parking is available onsite.


text:
What is the Fractional CO2 laser and the Fraxel laser?
The Fractional CO2 and Fraxel lasers are fractional laser treatment used for treating sun spots, fine lines, stretch marks, acne scarring, surgical scarring and traumatic scarring. The Fractional CO2 lasers can minimize the appearance of surgical and traumatic scars in just 1-2 treatments. The most popular examples of Fractional CO2 lasers are the MiXto, TotalFX and Fraxel.
What does it mean to be a fractional laser?
Fractional lasers treat microscopic areas of the skin in each pulse, leaving the surrounding area intact. Treating the skin in this way allows for faster healing, compared to traditional resurfacing lasers. Using a fractional laser is safer and often more effective than the older non-fractional lasers.
What types of scars can be treated with Fractional CO2 lasers?
Fractional CO2 lasers, such as the MiXto, are very effective for many types of scarring. They can be used effectively for the revision of surgical scar removal. Scars that don't look the way you hoped can usually be revised and improved upon with only 1 Fractional CO2 treatment or a series of Fraxel laser treatments. This can be done on any part of the body.
How do Fractional lasers work?
The Fractional lasers produce numerous microscopic laser columns that penetrate into the deeper layers of the skin to stimulate your skin's own healing process. The damaged skin is then replaced with collagen produced by your own body. The result is a smoother, healthier appearing scar.
Will Dr Schweiger use the Fraxel or Fractional CO2 laser on my scar for removal?
After a consultation in our midtown Manhattan office, Dr. Schweiger will determine if the Fraxel, the Fractional CO2 laser or a combination is best to treat your surgical scar.
Are Fractional lasers safe to use on surgical and traumatic scars?
Yes, the Fractional CO2 laser and the Fraxel laser are very safe and effective for the treatment of scarring. They are safe to use on all healed surgical scars and will not compromise the surgery in any way.
Are Fraxel laser treatments safe to use in darker skin types?
Dr. Schweiger safely treats scars in patients with all skin types including Asian, Indian, and African-American skin. An experienced laser surgeon is needed to treat darker skin types safely.
What should I expect during my visit?
After your initial consultation, we will determine the best course of action for the treatment of your scar. The treatment will be done in the NYC office of Schweiger Dermatology in Manhattan.
Upon arrival, we will cleanse the skin and apply a topical anesthetic to the skin surface. It will take approximately 60 minutes for the aesthetic to take effect. The anesthetic will then be removed and the Fractional laser treatment will begin. The actual treatment takes between 10-30 minutes, depending on the size of the scar. You will have only very minimal discomfort during the procedure. After the treatment, the treated area will be very red and you will need to cover the area with ointment for the first few days.
How much do Fractional Laser treatments for surgical and traumatic scars cost?
The price of Fractional treatments for scars varies by the size of the scar and the area treated. During your visit, NYC dermatologist Dr Schweiger will determine the best laser for you and discuss the price before treatment.


text:
Search billions of records on Ancestry.com
Welcome to Floyd County, Kentucky
Our History
On December 13, 1799, the Kentucky General Assembly passed legislation to form Floyd County as the 40th county of Kentucky. The county was made from parts of
The county was named for James John Floyd. The county seat was Preston's Station, located on the Levisa Fork of the Big Sandy River and was later renamed Prestonsburg. It was founded in 1797. The first court house burned down on April 8, 1808, destroying all the early records, so the earliest records of government activity come from the year 1808. Prestonsburg was used as a Confederate stronghold during the Civil War and two battles took place nearby: the Battle of Ivy Mountain on November 8, 1861 and the Battle of Middle Creek on January 10, 1862. Both were Union victories. The first post office opened in 1816 as Floyd Court House.
Also located in Prestonsburg is the
I am the new coordinator for this Floyd County, KYGenWeb site. My name is Suzanne Shephard. Please feel free to contact me or my Assistant coordinator, Rick Reed with submissions, problems or whatever you may need.. I do not live in Floyd Co. but am a descendant of Anthony & Mary Heppel Hall.
Floyd County's web site is undergoing major renovation! Please excuse any broken links or problems that you might find. I'll have the site back up and running in no time!! Thanks!
Microsoft Excel File Viewer May Be Downloaded From Here
Adobe Reader May Be Downloaded From Here
Floyd County Times Online!
County Formation Maps
Knott2 Very good Site with Knott Info
Floyd County Archives
Kentucky Archives
Floyd County Map
Kentucky Vital Statistics Project
The KYGenWeb Project
In March and April, 1996, a group of genealogists organized the Kentucky Comprehensive Genealogy Database. The idea was to provide a single entry point for all counties in Kentucky, where collected databases would be stored. In addition, the databases would be indexed and cross-linked, so that even if an individual were found in more than one county, they could be located in the index.
At the same time, volunteers were found who were willing to coordinate the collection of databases and generally oversee the contents of the web page.
Sherri Bradley is the coordinator for the state of Kentucky. If you are interested in hosting a county page or helping to host one, please contact her.
East Kentucky Churches and Organizations Responding to Emergencies - EK-CORE
Kentucky Historical Society
Friends of the Samuel May House
Kentucky Highlands Project
Kentucky Births 1911 - 2001
©Copyright 2013 by Floyd County Genealogy Project All files on this website are copyrighted by their submitter and creator. They may be linked to, but may not be reproduced on another website or in any other form, without specific permission of the submitter, owner, publisher and this site moderator. Although public records are as such not copyrightable, the manner in which they are presented, including the notes, comments, etc. are. The information on this site is provided free of charge, by volunteers, for your personal use only. If you have records that you'd like to see added to this site, please contact Sherri or Suzanne and we'll be glad to add them to this collection.
If you have arrived at this site via a paid subscription database service, please know that the data contained on KYGenWeb Project sites has been donated by hardworking volunteers and has been providing genealogical data and information, as well as help for researchers, free of charge since 1996.
coming soon!
Floyd Co. Historical & Genealogical Society
OUR YESTERDAYS 10 years ago20 years ago30 years ago40 years ago50 years ago60 years ago
70 years ago


text:
Kolkata to Gangtok
Since Gangtok does not have a railway station, direct trains from Kolkata are not available. New Jalpaiguri, which is 148 km from Gangtok, is the nearest railhead. Saraighat Exp and Darjeeling Mail are some of the direct trains that take tourists from Kolkata to New Jalpaiguri in 10 hours. From the station, buses and taxis are available for Gangtok that will cover the 148 km long distance in 5-6 hours. Buses are among the most economical and comfortable mode of transport between Kolkata and Gangtok. Direct buses from Kolkata till Siliguri are available 4 times in a day and charge Rs 550 for 18 hours journey. From Siliguri tourists need to change the bus for Gangtok which is available 5 times during the day and cost Rs 450 onwards per person. One can avail taxi services if they like to travel via road to enjoy the scenic vista. The fare of the taxi ranges from Rs 13,000 to Rs 19,000 for a round trip from Kolkata.
Gangtok Packages
People who viewed this page also viewed


text: Adobe's many tools are well understood and valued by both graphic designers and software developers. Now, Adobe is making a major move "up market" to appeal to the marketers who plan and implement product marketing strategies, who oversee customer experience, and who control agency budgets. Adobe's acquisition in 2009 of Omniture—a major web analytics platform and closed loop marketing environment—has provided the company with the opportunity to both move "up market" and to flesh out an end-to-end platform and ecosystem. One of our Senior B2B marketing consultants, Sue McKittrick, attended Adobe's Omniture Summit this month to rub shoulders with many of Adobe's customers. Her takeaway: Adobe is successfully repositioning itself as an end-to-end platform for marketers. At the summit, Aseem Chandra, Omniture's VP of Marketing, referred to marketing as "the new finance" because it can now measure the pulse of the business in a way that only finance could have in years past. Think about it. Finance tracks the value chain of the business. It's important, but mostly inward facing. By contrast, marketing's aim is to "know and understand the customer so well the product or service fits him and sells itself.1" Facing outward, the marketer sees where the business is heading. Analytics provide the real-time monitoring tools that enable marketers to spot opportunities, sense trends, and shift quickly. Finance provides the rear-view mirror.


text:
Celebrate the Foods and Culture of Brazil at Central Market with Passaporte Brazil
Photos by Mai Pham |
For two weeks of every year, Central Market holds what in essence is an international festival in its stores by paying homage to the food and cultures of the another country. Three years ago, I attended my first "Passport" event when they celebrated the foods of Argentina. The following year, it was Spain, and then last year, it was France.
This year, Central Market is giving its customers "Passaporte Brazil," two weeks of food, cooking classes, music and more, dedicated to all things Brazil. They kicked it off in the usual style with a huge white tented party this past Thursday evening.
The kickoff party usually reflects the personality of the country. Last year, it was a more formal, seated affair that embodied the elegance of French dining. This year, the party was staged more informally as a walkabout buffet, with cocktail tables, a large dance floor for dancing and a stage set up for a live samba band to get everyone in the party spirit.
Party guests were greeted with freshly cut coconuts and fresh-pressed sugarcane drinks as they arrived. Inside the tent, festively dressed servers sporting straw hats served hors d'oeuvres of quince and queso fresco, hearts of palm canapes, and cheese bread.
As you walked around the room, different tables offered a choice of starters, coffee, beer or wine, and entree. For starters, I really enjoyed the small round black eyed pea fritters called acaraje, a type of Brazilian street food, were slit with a knife, then topped with tangy salsa, bechamel and shaved okra. The fritters were crispy and fun, with a good balance of creaminess and acidity from the toppings.
Traditional Brazilian feijoada. |
A delicious traditional black bean stew with beef and pork or, feijoada, was served with rice and small pickled red peppers, earning two thumbs up from a few Brazilian ex-pats from the Brazilian-owned Tramontina retail factory in Sugar Land.
Grilled chicken, stuffed tomatoes, roasted plantains, and traditional salads, like the hearts of palm salad, or the Sao Paolo salad with apples, peas, grapes and carrots, were also on offer as well, examples of dishes that will be served in the Central Market prepared food section.
For dessert, guests were treated to sumptuous Brazilian bonbons, or brigadeiros, in dark or white chocolate. So delicate they practically melted in your hand as you held them, the super smooth, sweet bonbons tasted like a freshly made chocolate truffle without a hard outer shell -- these will also be on sale inside Central Market.
We were also given a demonstration of Brazilian fight dance, or capoeira, presented by a local company of dancers, before the samba band took over with the music of Brazil.
The kickoff party just marks the beginning of the two-week Brazilian celebration. During the week, stands will be set up in front of the store to showcase Brazilian drinks and Brazilian food. There are cooking classes, as well as wine and coffee classes offered through the Central Market cooking school. Brazilian prepared foods will be ready made for easy takeout. Brazilian's best flip flops -- Havaianas-- will also be on sale. And in the produce section, don't miss a huge selection of exotic, colorful, tropical fruits typical of Brazil.
Passaporte Brazil takes place at Central Market for two weeks only -- April 24 through May 7, 2013. For more information, and a schedule of events, please visit http://www.centralmarket.com.
Follow Eating Our Words on Facebook and on Twitter @EatingOurWords
Related Location
In Case You Missed It
Popular Stories
Sponsor Content


text:
Monster Turbine Pro Copper In-Ear Headphones
" I was selected to review these headphones in exchange for honest review, that review follows: I have used a lot of different headphones of varying prices and have been enjoying the Monster Turbine Pro Copper headphones ever since I received them. In short, they are now my IEMs of choice. Before even listening to the headphones, I was impressed by the packaging and the way I could..." --schalliol
Miles Davis Trumpet High Performance In-ear Headphones
"Sound is neutral with a slight mid bass tilt. Highs and lows are well extended. Sound stage is large for an iem. The bass has some impact without being boomy. The treble is clear without roughness. Don't pull hard on the cable. The strain relief is not strong. Hold the Trumpet by the "mouthpiece" end when handling them. If you have the..." --Merfolk
Monster Turbine Pro Gold In-Ear Headphones
" Well, this has been quite the turn of events! I had auditioned a full-sized Monster headphone, which I felt rather negative about, but the Turbine Pro Gold (TPG from here on) caught me quite off guard. Overall, the TPGs are excellent sounding, have superior build quality to many earbuds and IEMs I've owned/seen and offer a wide array of tips for fitted comfort, so let's explore what makes..." --Landis
Bowers & Wilkins C5 S2 In-Ear Headphones, Black
"I've repeatedly tried to use in-ears over the years, as over-ears take too much space in my cabin luggage, but hated each and any model/make when walking or running because of the mechanical noise transmitted via the bone system. I've bought me a B&W C5 S2 after the shop staff at the airport surprisingly remarked the importance of a thorough listening test before any purchase, which is..." --rbbrnck
iBeats Headphones with ControlTalk From Monster® - In-Ear Noise Isolation - Black
"So I'm relatively new to the world of high end headphones, and I've started by experimenting with over the ear cans, I'll move onto IEMs eventually, but I feel like these guys get a bad rap. As for what I like, I like to listen to my electronic music, so the bright (and not overshadowed) highs and thumpy bass make for a good, enjoyable time. I wish the mids were as present, but this is..." --AtomikSound
Monster Miles Davis Tribute Jazz In-Ear Headphones
" I would say that burn-in is a must for this earphone. Before burn-in, the earphone sounded unimpressive. I almost wanted to return or sell it off. It sounded so much better after burn-in. The first thing that I noticed is the bass. There is a good quantity of it (once you get a good seal) but it is not muddy at all. It was very punchy. Using it for movies proved quite..." --regleo
Bowers & Wilkins C5 In-Ear Headphones
" I bought these to replace my beloved A-Jays four. I needed something with the integrated in-line ipod/iphone controls, but with a bit better audio-quality, and some that may not pop out as easily as the JAYS. These have a "secure loop" system which provides an adjustable cable loop that tucks into your upper ear, helping to keep the buds in place. I personally found..." --Dneale
Bowers & Wilkins C5 Series 2
" Using TheHeadphoneList's Review Format Below Accessories - 3/5 You get a semi-hard case with a felt-like exterior that zips up and 3 different sized tips to help fit your ears. Silicone style tips. I was actually able to get a great seal with the stock tips which was a shock to me, as my two ear canals are typically different enough to warrant different sizes. Most..." --RubxQub
Monster Diddy Beats In-Ear Headphones
"I bought these a year ago for $150. If you have a decent home theater system and you have a club, jazz or disco preset, that's what these sound like. They have a fun grungy club sound to them. I think they are overpriced for what you get, at the time I didn't know any better comming from apple earbuds and JVC Gummies. The bad think about these is they are HEAVY. I weighed theses against..." --JonnyRocket
Monster Gratitude In-Ear Headphones
"Thought I'd give a little love to this iem and write a quick review for it. In my opinion, its one of the closest that monster has gotten to its typical description of "clear highs, smooth mids, and punchy dynamic bass." Build Quality: These are definite build better than some of the other monster iems. Feels sturdy in its metal housing and the right angle jack feels sturdy. The right..." --Cotnijoe


text:
SAN FRANCISCO (Reuters) - Online music-streaming service Spotify has raised $250 million in a new funding round, making it one of the world's most richly capitalized start-ups.
The new funding round was led by Technology Crossover Ventures, a Silicon Valley-based venture-capital firm, a person familiar with the matter said on condition of anonymity because the deal is private.
The cash can help the Swedish music service bolster its U.S. business, which trails services such as Pandora, and launch in other countries such as Japan. The newest financing brings the value of Spotify to more than $4 billion, according to the Wall Street Journal, which first reported the funding round on Thursday.
Spotify raised $100 million last year from investors including Goldman Sachs. In 2012, it raised $100 million from investors including Kleiner Perkins and Digital Sky Technologies.
Just a handful of start-ups, including daily deals site Living Social, online bulletin board Pinterest and online survey tool SurveyMonkey, have raised more than $400 million.
In July corporate filings in Luxembourg, where Spotify is registered, showed the company more than doubled revenue in 2012 to 435 million euros ($571 million), while its net loss increased to 58.7 million euros from 45.4 million a year earlier.
The business, launched in October 2008, strikes royalty deals with record labels and pays about 70 percent of its revenue back to rights holders. Spotify has about 24 million active users, of whom 6 million pay for a premium service, spokeswoman Alison Bonny said. It operates in 32 countries.
She declined to comment on the funding round.
Streaming and on-demand music have soared in popularity alongside smartphone use, but companies like Spotify and Pandora - which has almost 68 million active listeners - have struggled to make profits due to the cost of royalty fees.
Earlier this year, Apple Inc introduced its iTunes Radio product, which is similar to Pandora, Spotify and other competitors.
(Reporting by Sarah McBride; Editing by Richard Chang)


text:
Drama Review 'The Excellent Wife' Episode 8
While Hye-kyeong is busy with this hard case, we get an easierglance at Tae-joon and Joong-won, their mind and emotions for the girlin addition their morality. Some dark facts surface in episode 8 and the complete lotresults in a homicide and a new crisis. As smartly as her work, Hye-kyeong continues to handle two men who have their own ideas more or less what she wishes while she tries to stay her circle of relatives afloat.
I acknowledged in my review for episode seven that Hye-kyeong (Jeon Do-yeon) would be at risk when facinga perilouscrook like Jo Gook-hyeon (Go Joon) and while I used to be right, it form of feels she could have worse folks to face, addingthe only she is recently married to. I could bein a position tocommunicate more about Tae-joon's (Yoo Ji-tae) machinations and imaginable crimes in a bit, yet his habit toward Hye-kyeong isn'tpreciselyanything he will also behappy with either.
Advertisementane had up to now assumed that he's fake, manipulative and narcissistic and while the latter two still stand, he does have some twisted honesty in his feelings for his wife. There's aerroneous sense of "love" there, which in Taejoonland way that he is enthusiastic about having her and keeping her what he considers to be safe. Unfortunately, that impliesdismissing her entirely, mendacity to her, the use of her and let me know if I must continue with this, because I have a list.
His plans for her come withemploying Joong-won's (Yoon Kye-sang) feelings for her to get his way and as lousy as this is, the receiving finish of that temptation is now not doing wonderful either. Joong-won still commits immoral acts to put into effect his coverage on Hye-kyeong, which she never asked for. At the similar time, he is acutely conscious of his flaws. Dan (Nana) issues this out and while knowing larger arguably makes him worse than Tae-joon at the moment, it suggests that he has some hope for redemption. Tae-joon does not.
Despite his behavior as a husband, I'm going to not call him a assassin just yet. He had each and everyreason why and opportunity to harm Amber as well, but he did not, no less thanso a long way as we know. Sang-il (Kim Tae-woo) is solely equally shady and mean as a character, so I believe him perfectly able to this act. Whatever they are doing, I stay up for the day Hye-kyeong teaches either a lesson.
As vital as it's milesto understand Tae-joon and Joong-won better, I do feel the ultimate two episodes are sidelining her studiesoutdoor of the triangle a bit. They are more about the men's needs and morality than they are about her. As the titular personality she wants to reclaim firm and control, so I am hoping that here is where the 2d onepart of the series will take us.
"The Excellent Wife"is directed byLee Jeong-hyo, written byHan Sang-woonand featuresJeon Do-yeon,Yoo Ji-tae,Yoon Kye-sangandKim Seo-hyeong.


text:
Once a month we will meet to review some research and statistics articles from Pediatrics in Review that are available on the Journal Club website and then cover a specific journal article. We will coordinate the type of journal article we review with the lessons assigned for the meeting. There are questions related to different types of articles on the website that we will use to help discuss each article. These lessons are 2 – 3 pages at most and should not take more than 30 minutes or so to read in addition to time finding an appropriate article.
Here is an excerpt from the first article in the series we will be using. "In late 2008, the ABP added 26 new content specifications on research and statistics. To cover these, we introduce a new series. Clinician researchers from the Johns Hopkins University Division of General Pediatrics and Adolescent Medicine will be writing brief case-based or practice-oriented articles to address these topics. We hope that these articles will be useful for readers in evaluating the scientific literature and adopting evidence-based practice."
We will not have time during the meeting to read the entire journal article as was done in the past. The time will be spent reviewing the lesson and questions, 15 minutes, and then reviewing the article for its content and how it relates back to the lesson, 30 minutes.
Each presenter will pick an article to review and then send the article to me for acceptance and uploading to the Journal Club website. If for any reason someone can't meet their obligation for the month they must exchange dates and topics with another on the list who will then present the material assigned for that month.Click here to view "How to Write a Case Report".
Past Articles: Impact of Family Presence During Pediatric Intensive Care Unit Rounds on the Family and Medical Team Length of Intravenous Antibiotic Therapy and Treatment Failure in Infants with Urinary Tract Infections Interns Overestimate the Effectiveness of Their Hand-off Communication Methods of Investigation and Management of Infections Causing Febrile Seizures Quality of Care for Children Hospitalized With Asthma Effect of prophylactic paracetamol administration at time of vaccination... The Crying Infant: Diagnostic Testing and Frequency of Serious Underlying Disease Characteristics of Cognitive Functions in Children's with Epilepsy The Crying Infant: Diagnostic Testing and Frequency of Serious Underlying Disease Is There Cross-Reactivity Between Penicillins and Cephalosporins? Lipid Screening and Cardiovascular Health in Childhood Macrogol (polyethylene glycol) laxatives in children with functional constipation and faecal impaction: a systematic review Oral Probiotics Prevent Necrotizing Enterocolitis in Very Low Birth Weight Preterm Infants: A Multicenter, Randomized, Controlled Trial Food Allergies Unnecessary Milk Elimination Diets in Children with Atopic Dermatitis Patterns of Care and Referral in Children with Atopic Dermatitis and Concern for Food Allergy IgG to Foods: A Test Not Ready for Prime Time Screening for Type 2 Diabetes in Obese YouthQuestions for an article about Therapy.Questions for an article about Diagnostic Tests.Questions for an article about Harm.Questions for an article about Prognosis.Questions for Meta-Analysis and Review Articles.